Lenvatinib en el tratamiento sistémico de primera línea en Cáncer Diferenciado de Tiroides Refractario a Radioyodo

4 / 27

Survival of RAI-Refractory DTC Patients Decreases
Significantly Compared With RAI-Avid Patients
• Median survival for patients with RAI-refractory DTC and distant
metastases is estimated to be less than 3 years1,2
Years After Metastasis Discovery
0 5 20 30 40 10 15 25 35
0.0
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
1.0
0.9
Survival
131 I uptake
No 131I uptake
• Patients are often subject to multiple complications associated with disease
progression2
4
RAI-refractory DTC
5-year survival: < 50%
10-year survival: 10%
OS, overall survival.
Durante C, et al. J Clin Endocrinol Metab . 2006;91(8):2892-2899. 2. Pfister DG, Fagin JA. J Clin Oncol. 2008;26(29):4701-4704. 3. Brose MS, et al. Presented at
ASCO 2014. Poster 6060.